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Abstract
Background
Of two community-based trials among young children in neighboring health districts of Bur-
kina Faso, one found that small-quantity lipid-based nutrient supplements (LNS) increased
child growth compared with a non-intervention control group, but zinc supplementation did
not in the second study.
Objectives
We explored whether the disparate growth outcomes were associated with differences in
intervention components, household demographic variables, and/or children’s morbidity.
Methods
Children in the LNS study received 20g LNS daily containing different amounts of zinc
(LNS). Children in the zinc supplementation study received different zinc supplementation
regimens (Z-Suppl). Children in both studies were visited weekly for morbidity surveillance.
Free malaria and diarrhea treatment was provided by the field worker in the LNS study, and
by a village-based community-health worker in the zinc study. Anthropometric assessments
were repeated every 13–16 weeks. For the present analyses, study intervals of the two stud-
ies were matched by child age and month of enrollment. The changes in length-for-age z-
score (LAZ) per interval were compared between LNS and Z-Suppl groups using mixed
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ferences between group means were estimated.
Results
Mean ages at enrollment of LNS (n = 1716) and Z-Suppl (n = 1720) were 9.4±0.4 and 10.1
±2.7 months, respectively. The age-adjusted change in mean LAZ per interval declined less
with LNS (-0.07±0.44) versus Z-Suppl (-0.21±0.43; p<0.0001). There was a significant
group by interval interaction with the greatest difference found in 9–12 month old children
(p<0.0001). Adjusting for demographic characteristics and morbidity did not reduce the
observed differences by type of intervention, even though the morbidity burden was greater
in the LNS group.
Conclusions
Greater average physical growth in children who received LNS could not be explained by
known cross-trial differences in baseline characteristics or morbidity burden, implying that
the observed difference in growth response was partly due to LNS.
Introduction
Linear growth restriction in early life continues to be a critical public health concern. Growth
stunting is associated with increased mortality risk, impaired cognition and educational per-
formance, lower adult wages, and, when accompanied by excessive weight gain later in child-
hood or adulthood, increased risk of nutrition-related chronic diseases [1]. The sustainable
development goal 2.2 aims to end all forms of malnutrition by the year 2030, which includes
achieving the global target to reduce the number of stunted children under 5 years of age by
40% by 2025 [2,3]. Although stunting has decreased slowly worldwide [4], achieving these
goals poses a challenge. It is well-recognized that stunting is caused by many risk factors,
including intrauterine growth restriction, inadequate breastfeeding and complementary feed-
ing practices, household and family factors and repeated infection [5]. Thus, the expected
impact and cost-effectiveness of nutritional interventions may vary according to these under-
lying risk factors.
The complementary feeding period, generally corresponding to the 6–24 month age range,
is a particularly vulnerable period for growth faltering and therefore an important time to
intervene. Small-quantity and medium-quantity lipid-based nutrient supplements (LNS) offer
a promising strategy to improve the nutritional quality of local complementary foods [6].
Small-quantity LNS provide ~20 g or ~110–120 kcal per day and medium-quantity LNS ~50 g
or ~250–280 kcal per day along with additional protein, essential fatty acids and 22 micronu-
trients [6]. While larger quantity LNS has proven useful in the treatment of children with mod-
erate or severe acute malnutrition [7,8], the potential of smaller quantities of LNS to prevent
malnutrition and increase growth is still being explored, with inconsistent effects on young
children’s growth outcomes across studies in different settings [9–13]. One of the studies with
a significant impact on children’s growth was conducted in south-western Burkina Faso. Chil-
dren 9–18 months of age who received 20 g LNS daily along with illness treatment for malaria
and diarrhea had significantly greater length and reduced stunting at 18 months of age com-
pared to a non-intervention cohort [14]. Because the control group in this study was a non-
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intervention control group that did not receive small-quantity LNS, illness treatment or home
visits, it is not clear how much of the growth impact was due to small-quantity LNS and/or ill-
ness treatment and how much was due to other aspects of the study design and study popula-
tion characteristics. Thus, one of the key questions remaining is whether LNS was solely or
partially responsible for the growth impact observed in Burkina Faso.
Another promising intervention to prevent childhood stunting is preventive zinc supple-
mentation. Meta-analyses investigating the impact of preventive zinc supplementation found
that 5–10 mg supplemental zinc daily has a small, but significant impact on linear growth and
weight gain in prepubertal children [15–18]. This is in contrast to the recent findings among
young children in Burkina Faso, where children 6–30 months of age who received daily pre-
ventive zinc supplementation, intermittent preventive zinc supplementation or therapeutic
zinc supplementation gained slightly less length than children who did not receive any zinc
supplements (3.15–3.20 cm vs. 3.36 cm over 16 weeks, p<0.001) [19]. The zinc supplementa-
tion study and the LNS study in Burkina Faso mentioned above were implemented in neigh-
boring health districts using similar protocols, and therefore provide a unique opportunity for
exploratory analyses of the reasons for these different growth outcomes. The purpose of the
present paper is to assess whether the different growth outcomes were associated with differ-
ences in study design and form of supplementation, other aspects of the intervention design,
demographic variables, or child morbidity in the two study populations.
Material and methods
Study design and procedures
Data from two studies are included in the present analyses. The LNS and the zinc supplemen-
tation studies were both partially masked, placebo-controlled, cluster-randomized interven-
tion trials in neighboring health districts of southwestern Burkina Faso. The LNS trial was
conducted from April 2010 to July 2012 in the Dande´ Health District, and the zinc trial was
conducted from December 2010 to February 2012 in the Orodara Health District. Ethical
approvals for both study protocols and the consent procedures were issued by the Institutional
Review Boards of the Centre Muraz in Bobo-Dioulasso (Burkina Faso) and the University of
California, Davis (USA). The studies were registered as clinical trials with the U.S. National
Institutes of Health (www.ClinicalTrials.gov; NCT00944281 and NCT00944359).
Study procedures, participant characteristics and results of primary outcomes of both stud-
ies have been described in detail elsewhere [14,19] and are summarized briefly below. In both
studies, communities were randomly allocated to intervention cohort (IC) or non-intervention
cohort (NIC; Fig 1). In the intervention cohort of the zinc study (Z-IC), during each of the
three intervals randomly selected clusters served as non-supplemented morbidity surveillance
comparison group (Z-Contr) for the zinc supplemented groups (Z-Suppl). In both studies,
children in the intervention communities were randomly assigned at the concession level (i.e.
extended family compound) to different intervention products and supplementation sched-
ules. Within the LNS-IC communities, eligible children were randomly assigned to receive a
20 g daily ration of LNS containing 0, 5 or 10 mg zinc [14]. Within the Z-IC, eligible children
were randomly assigned to 1) intermittent preventive zinc supplementation (10 mg zinc for
10 days) every 16 weeks and daily preventive and therapeutic placebo tablets, 2) daily preven-
tive 7 mg zinc tablet and therapeutic placebo during diarrhea, and 3) therapeutic zinc supple-
mentation for episodes of diarrhea (20 mg zinc/ day for 10 days) and daily placebo tablets [19].
The LNS products and zinc and placebo tablets were produced by Nutriset SAS (Malaunay,
France). The LNS for each treatment group were identical, except for their zinc content; and a
daily LNS ration provided 118 kcal and 21 other micronutrients [6].
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Children were eligible for the LNS study if they were 8.8 to 9.9 months of age, and for the
zinc study if they were 6–27 months of age. Additional inclusion criteria were permanent resi-
dence in the study area, planned availability during the study period and written parental con-
sent. Main exclusion criteria were: hemoglobin (Hb) <50 g/L, weight-for-length <70% of the
median of the National Center for Health Statistics/World Health Organization (NCHS/
WHO) growth reference [20], presence of bipedal edema, other severe illness warranting hos-
pital referral, and congenital abnormalities potentially interfering with growth.
At enrollment, children’s length, weight and mid-upper arm circumference (MUAC) and
maternal height and weight were measured. Information on children’s dietary practices [21]
and household socio-economic status (SES) was obtained. A capillary blood sample was col-
lected for analyses of hemoglobin (Hb) concentration (Hemocue 201+, HemoCue1 AB,
Fig 1. Study design of the LNS and the zinc supplementation studies. Children eligible for the present
long-term and short-term exploratory analyses were matched by age. 1 In LNS study area, cluster
randomization of 34 communities to intervention cohort (LNS-IC, 25 communities) or non-intervention cohort
(LNS-NIC, 9 communities). 2 In zinc supplemenation study area, 36 geographically defined clusters, were
randomly assigned to one of three cohorts: immediate and delayed intervention (Z-IC, 12 clusters each), and
non-intervention cohort (Z-NIC, 12 clusters). 3 Children in LNS-IC, LNS-NIC, Z-IC, and Z-NIC who participated
during the full study period were included in the analyses of the full study duration. 4 Within the LNS-IC
communities, eligible children were randomly assigned to 1) LNS without zinc, and placebo tablet, 2) LNS with
5 mg zinc, and placebo tablet, 3) LNS with 10 mg zinc, and placebo tablet, or 4) LNS without zinc, and 5 mg zinc
tablet. Children diagnosed with uncomplicated diarrhea, malaria and fever received free medical treatment
during weekly home visit. 5 Within the Z-IC, eligible children were randomly assigned to 1) intermittent
preventive zinc supplementation (10 mg zinc for 10 days) every 16 weeks and daily preventive and therapeutic
placebo tablets, 2) daily preventive 7 mg zinc tablet daily and therapeutic placebo during diarrhea, and 3)
therapeutic zinc supplementation for episodes of diarrhea (20 mg zinc/ day for 10 days) and daily placebo
tablets. Children diagnosed with uncomplicated diarrhea, malaria and fever received free medical treatment
from a village-based community health worker. 6 During each of the 16 week-rounds in the Z-IC cohort, three
randomly selected clusters served as non-supplemented morbidity surveillance comparison group (Z-Contr).
Children diagnosed with uncomplicated diarrhea, malaria and fever received free medical treatment from a
village-based community health worker. 4,5,6 Children were matched by age and month of enrollment for
inclusion in the analyses of age-specific intervals: 9–12 mo interval, 12–15 mo interval and 15–18 mo interval. 7
In both studies, children in the NIC were assessed at enrollment and at the end of the study and did not receive
any supplementation of morbidity treatment throughout the course of the study.
https://doi.org/10.1371/journal.pone.0181770.g001
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 4 / 19
A¨ngelholm, Sweden) and a rapid diagnostic test (RDT) was performed for malaria parasites,
based on histidine-rich protein II (SD BIOLINE Malaria Ag P.F/Pan, Standard Diagnostics,
INC., Kyonggi-do, Korea). In case of illness, all children screened at enrollment for both stud-
ies received free medical treatment(s): oral rehydration salts (ORS) packets were provided for
cases of diarrhea, and anti-malarial treatment was provided based on a positive RDT (artesu-
nate-amodiaquine combination therapy in the LNS study and artemether-lumefantrine com-
bination therapy in the zinc study), and paracetamol was provided to children with reported
fever. Children with Hb <80 g/L received anthelmintic treatment (mebendazole 200 mg/day
for 3 days) and iron supplements (2–6 mg iron/kg body weight for 30 days).
Anthropometric assessments were repeated every 12–13 weeks among children in the LNS-
IC and every 16 weeks among children in the Z-IC (which includes Z-Suppl and Z-Contr).
Length-for-age z-score (LAZ), weight-for-age z-score (WAZ), weight-for- length z-score (WLZ),
and z-scores of body mass index (BMIZ) and mid-upper arm circumference (MUACZ) were
calculated using the WHO growth standards [22,23]. A dedicated field worker visited homes of
all children in the LNS-IC and Z-IC cohorts weekly to record morbidity symptoms for each of
the past 7 days. At each visit, the field worker evaluated the child for the presence of clinical dan-
ger signs, and evidence of diarrhea, fever, or malaria. In case of reported fever on the day of or
the day before the surveillance visit, the field worker performed an RDT and measured body
temperature. Although the illness treatment protocol was comparable between the two studies,
an important difference related to the site of treatment provision. In particular, for children in
the LNS-IC, the field worker provided free treatment at the time of diagnosis during the home
visit [14,24]. By contrast, in the Z-IC cohort of the zinc study (i.e. in the Z-Suppl and Z-Contr),
children did not receive treatment directly from the field worker, but were encouraged to visit
the project-trained community-health worker in their village of residence to receive free treat-
ment [19]. Children with danger signs, or diarrhea, fever or malaria with complications and any
other cases of severe illness were referred to the health center for evaluation and treatment in
both studies. Children in LNS-NIC and Z-NIC had no further contact with the study team until
the endline assessment and therefore were not measured at interim time points and did not
receive intervention products, morbidity surveillance or free illness treatment.
Statistical analyses
The objective of the analysis was to examine whether the different growth outcomes of the
LNS and zinc trials could be explained by factors that differed between studies, other than the
type of supplement. The general statistical approach was to estimate the difference between
study effects using a linear model without covariates, and then assess whether this estimated
difference was attenuated by including potential confounders in the model. If LNS had an
independent positive effect on growth, as hypothesized, this difference would remain statisti-
cally significant, although possibly of reduced magnitude.
Two separate analyses were conducted: analysis of growth over the “whole study duration”,
and analysis of growth over “age-specific study intervals”. Outcomes were change in LAZ,
WAZ, and WLZ over the whole study duration and the age-specific intervals in relation to
WHO growth standards [22].
Due to differences in the study design, all children in the LNS study, but only some of the
children in the zinc supplementation study were included in the analyses over the whole study
duration (Fig 1), which was approximately 39 weeks for the LNS study and 48 weeks for the
zinc supplement study. Because the two studies included children of different ages and were
implemented not completely at the same time, the following criteria were used to match par-
ticipants of the two studies for the “whole study analysis”: children who had measurements at
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 5 / 19
baseline and endline of study, for whom the date at midpoint could be matched between the
two studies, and whose age at midpoint was between 13.0 and 15.0 months inclusive (Fig 2A).
For the zinc supplementation study, outcomes were first compared between children who
started with an initial non-supplemented morbidity surveillance period (Z-Contr) vs. those
who started with supplementation (Z-Suppl); as there were no significant differences in growth
outcomes over the full 48-week period, both groups of children were included in the analysis
as Z-IC. Similarly, for the “age-specific analysis” inclusion criteria were: intervals for which
there were measurements at the beginning and end, for which the dates at midpoint could be
matched between the two studies, with child age at midpoint between 10.0 and 12.0 mo (9–12
mo interval) or 13.0 and 15.0 mo (12–15 mo interval) or 16.0 and 18.0 mo (15–18 mo interval),
and for which the duration was between 2.1 and 4.3 mo (Fig 2B).
For both analyses, potential explanatory variables were identified as variables that differed
between the two study samples, and therefore could be the source of the difference in the effect
of treatment between studies. Covariates were added to the models in blocks (Table 1) for bet-
ter understanding of the effect of each set of covariates. Morbidity covariates were not available
for the whole-study analysis because the non-intervention cohort did not have morbidity
measures.
For the whole-study analysis, the following basic variance components model was fit:
Yijklm ¼ b0 þ b1Si þ b2Cj þ b3SiCj þ gk þ dlðkÞ þ εijklm
where: Yijklm = Outcome (change in LAZ, WAZ, or WLZ) for child m in study i, cohort j, vil-
lage k, and concession l
Si = Indicator variable for study (LNS vs Zinc)
Fig 2. Age vs date at midpoint of study interval for whole-study and age-specific analyses of the LNS and the zinc supplementation study.
Intervals in the overlapping areas were eligible for inclusion in the analysis.
https://doi.org/10.1371/journal.pone.0181770.g002
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Cj = Indicator variable for cohort (IC vs NIC)
γk = Random effect for village k
δl(k) = Random effect for concession l nested within village k
εijklm = Error term for child m
The coefficient for the study by cohort interaction, β3, estimates the difference between
treatment effects in the two studies. Potential confounder variables, along with their interac-
tion with cohort, were then added to the model in stages:
Yijklm ¼ b
0
0
þ b
0
1
Si þ b
0
2
Cj þ b
0
3
SiCj þ
X
g
ðygXg;ijklm þ φgCjXg;ijklmÞ þ g
0
k þ d
0
lðkÞ þ ε
0
ijklm
where: Xg,ijklm = Value of covariate g for child m in study i, cohort j, village k, and concession l,
standardized to a mean of 0
The new coefficient for the study by cohort interaction, β3
’, estimates the theoretical differ-
ence between treatment effects in the two studies at the mean value of the covariates.
The analysis of age-specific intervals was carried out to better understand both the differ-
ence in treatment effects at different ages and the effect of morbidity variables on the treatment
differential. Individual intervals were designated according to the treatment received (LNS,
Z-Suppl, Z-Contr) in that interval. Because the NIC groups could not be included, due to not
having age-specific data, and there was no LNS control interval, the effects of the different
study interventions was examined by comparing the LNS and Z-Suppl groups, with the
Z-Contr group included in the analysis for informal comparison. A preliminary mixed models
Table 1. Components of mixed models used in the exploratory analyses of the whole study duration
and the age-specific intervals of the LNS and the zinc supplementation study among young Burki-
nabe children.
Model
number
Components of mixed model Cohorts / study
groups included
Whole study duration
A Fixed main effects of study (LNS vs. zinc study) and intervention
cohort (IC vs. NIC), along with a fixed interaction term and random
effects of village and concession within village
LNS-IC, LNS-NIC,
Z-IC, Z-NIC
B Model A + baseline anthropometric values (LAZ, WLZ), age at mid-
point and time between anthropometric measurements
LNS-IC, LNS-NIC,
Z-IC, Z-NIC
C Model B + sex of child, maternal height, BMI, age, marital status
(first wife), ethnic group, maternal education
LNS-IC, LNS-NIC,
Z-IC, Z-NIC
Age-specific interval
1 Fixed effect of group and random effects of village and concession
within village
LNS, Z-Suppl, Z-Contr
2 Model 1 + duration of interval (i.e. time between two anthropometric
measurements)
LNS, Z-Suppl, Z-Contr
3 Model 2 + age at midpoint of interval and season LNS, Z-Suppl, Z-Contr
4 Model 3 + child sex, maternal age, height, BMI, educational level,
marital status, and ethnic group, and anthropometric status at
enrollment
LNS, Z-Suppl, Z-Contr
5 Model 4 + prevalence of fever without malaria, prevalence of fever
with malaria, incidence of treated malaria, prevalence of diarrhea,
incidence of severe diarrhea, and prevalence of upper or lower
respiratory infection
LNS, Z-Suppl, Z-Contr
6 Model 5 + anthropometric variables at the beginning of the age-
specific interval (potentially mediating variables)
LNS, Z-Suppl, Z-Contr
https://doi.org/10.1371/journal.pone.0181770.t001
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analysis including fixed effects of group (LNS, Z-Suppl, Z-Contr), age interval (9–12 mo, 12–
15 mo, 15–18 mo), and group by age interval, and random effects of village, concession, and
subject, indicated that in general the group by age interval interaction was significant and ran-
dom effects of subject were minimal. Therefore, the analysis was conducted separately for each
age-specific interval, with the following basic variance components model:
Yiklm ¼ b0 þ b1G1i þ b2G2i þ gk þ dlðkÞ þ εijklm
where: Yijklm = Outcome (change in LAZ, WAZ, or WLZ) for child m in group i, village k, and
concession l
G1i = Indicator variable for LNS vs Z-Suppl
G2i = Indicator variable for Z-Contr vs Z-Suppl
γk = Random effect for village k
δl(k) = Random effect for concession l nested within village k
εijklm = Error term for child m
The coefficient for the indicator variable for LNS vs Z-Suppl, β1, estimates the difference
between the LNS and the Z-Suppl group means. Confounder variables were then added to the
model in stages:
Yijklm ¼ b
0
0
þ b
0
1
G1i þ b
0
2
G2i þ
X
g
ðygXg;ijklmÞ þ g
0
k þ d
0
lðkÞ þ ε
0
ijklm
where: Xg,ijklm = Value of covariate g for child m in group i, village k, and concession l, option-
ally standardized to a mean of 0
The new coefficient for the indicator variable for LNS vs Z-Suppl, β1’, estimates the theoret-
ical difference between the groups at the mean value of the covariates. Analyses were con-
ducted with the MIXED procedure in SAS for Windows, Release 9.4 (Cary, NC).
Results
Separate sets of analyses were completed for growth increments during the whole study dura-
tion and for age-specific intervals, so each set of results is reported separately below.
Whole study analysis
Baseline characteristics differed between studies (Table 2). Namely, children in the LNS study
were significantly older at enrollment than children in the zinc supplementation study (9.5 ±
0.4 months vs. 8.5 ± 0.6,<0.0001), and children in the LNS study tended to have lower mean
LAZ, WAZ, WLZ, and MUACZ. However, only baseline length and baseline LAZ remained
significantly different between studies after controlling for age. Mothers in the LNS study were
slightly older and taller, but had a lower BMI, and mothers in the zinc supplementation study
were more likely to have had any formal education. There were also some differences in moth-
ers’ marital status, religion and ethnicity. Based on these baseline comparisons between stud-
ies, differences in the study growth outcomes may in part be explained by differences in
baseline LAZ and baseline age of the children and maternal characteristics such as maternal
education, marital status, religion and ethnic group. Thus, to explore the change in growth
outcomes over the whole study period, we added those covariates that differed significantly at
baseline to the model, as described below.
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 8 / 19
Table 2. Comparison of baseline characteristics of children in the exploratory analyses covering the whole duration of the intervention trials.1
p-value3 p-value after controlling for age at
baseline3
LNS-IC LNS-NIC Z-IC2 Z-NIC study Intervention
cohort
study*
intervention
cohort
study Intervention
cohort
study*
intervention
cohort
N 402 129 261 207
Study duration
(wks)
38.4 ± 0.9 39.3 ± 0.7 48.2 ± 0.7 48.1 ± 0.8 <0.0001 0.012 0.012 n/a n/a n/a
Child characteristics at enrollment
Age (mo) 9.5 ± 0.4 9.5 ± 0.4 8.5 ± 0.6 8.5 ± 0.6 <0.0001 0.98 0.35 n/a n/a n/a
Male, n (%) 197 (49.0) 58 (45.0) 130 (49.8) 88 (42.5) 0.81 0.10 0.63 n/a n/a n/a
Hemoglobin
(g/L)
90.7 ± 15.6 90.0 ± 15.4 92.1 ± 15.1 92.5 ± 14.8 0.22 0.85 0.99 0.70 0.85 0.97
Length (cm) 68.7 ± 2.5 68.7 ± 2.4 68.0 ± 2.8 68.3 ± 2.8 0.005 0.37 0.63 0.047 0.36 0.47
Weight (kg) 7.4 ± 0.9 7.4 ± 1.0 7.3 ± 1.0 7.4 ± 1.0 0.99 0.36 0.35 0.13 0.36 0.31
MUAC (cm) 13.2 ± 1.1 13.1 ± 1.1 13.3 ± 1.2 13.5 ± 1.1 0.046 0.46 0.67 0.38 0.47 0.70
LAZ -1.28 ± 1.04 -1.24 ± 0.88 -1.04 ± 1.15 -0.83 ± 1.12 0.0001 0.13 0.34 0.045 0.14 0.37
WAZ -1.47 ± 1.05 -1.49 ± 1.11 -1.33 ±1.19 -1.08 ± 1.06 0.001 0.18 0.15 0.11 0.18 0.17
WLZ -1.01 ± 0.98 -1.09 ± 1.12 -0.95 ± 1.07 -0.75 ± 0.97 0.008 0.48 0.13 0.41 0.48 0.14
BMIZ -1.00 ± 0.98 -1.07 ± 1.12 -1.00 ± 1.08 -0.81 ± 0.98 0.076 0.51 0.15 0.48 0.51 0.16
MUACZ -1.05 ± 1.07 -1.09 ± 1.05 -0.88 ± 1.19 -0.68 ± 1.02 0.010 0.35 0.51 0.36 0.35 0.56
Breastfeeding in
past 24hrs, n
(%)
402 (100.0) 129 (100.0) 259 (99.6) 206 (99.5) n/a n/a n/a n/a n/a n/a
Minimum dietary
diversity, n(%)4
36 (9.0) 10 (7.8) 22 (8.7) 14 (6.8) 0.73 0.41 0.82 0.95 0.41 0.83
Maternal characteristics
Maternal age
(yrs)
27.8 ± 7.1 27.4 ± 5.7 25.8 ± 6.3 26.4 ± 6.4 0.002 0.78 0.25 n/a n/a n/a
Maternal height
(cm)
162.1 ± 5.8 162.0 ± 5.2 160.1 ± 6.1 161.6 ± 5.9 0.011 0.10 0.066 n/a n/a n/a
Maternal BMI
(kg/m2)
20.8 ± 2.6 20.8 ± 1.9 21.2 ± 2.4 21.8 ± 3.1 0.0008 0.13 0.22 n/a n/a n/a
Maternal
education, n (%
with any formal
education)
44 (11.0) 9 (7.0) 57 (22.0) 45 (22.7) <0.0001 0.41 0.29 n/a n/a n/a
Mother is first or
only wife, n (%)
289 (72.3) 91 (70.5) 156 (60.2) 118 (59.6) 0.003 0.72 0.94 n/a n/a n/a
Maternal religion 0.045 0.93 0.11 n/a n/a n/a
Muslim, n (%) 317 (79.1) 85 (65.9) 202 (79.2) 155 (79.1)
Traditional, n
(%)
42 (10.5) 39 (30.2) 46 (18.0) 26 (13.3)
Christian, n
(%)
42 (10.5) 5 (3.9) 7 (2.8) 15 (7.7)
BMI, body mass index; BMIZ, z-score of body mass index; LAZ, length-for-age z-score; MUAC, mid-upper arm circumference; MUACZ; z-score of mid-
upper arm circumference; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score
1 mean ± standard deviation (SD), and n (%); all such values.
2Some of the children in this sample participated in morbidity surveillance first for 16 weeks and subsequently received zinc supplements
3Comparison of baseline characteristics with mixed models ANOVA for continuous outcomes and mixed models logistic regression for categorical
outcomes, including random effects of village and concession.
4 Child received food from 4 or more food groups during the previous 24 h [21]
https://doi.org/10.1371/journal.pone.0181770.t002
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Adding initial LAZ, initial WLZ, child’s age at mid-point and time between length measure-
ments did not attenuate the study by cohort interaction coefficient for change in LAZ (model
B; 0.607 ± 0.123) compared with the simple model unadjusted for any covariates (model A;
0.529 ± 0.119; Fig 3). Similarly, the addition of maternal and child covariates that differed at
baseline, did not substantially attenuate the interaction coefficient (model C; 0.459 ± 0.152),
suggesting that the differences in final LAZ were not explained by these covariates (Table 3).
These findings were similar for WAZ. When exploring the change in WLZ, we found that
there was no significant study by cohort interaction term in the unadjusted model A. After the
addition of covariates, the interaction term became significant, suggesting that not just height,
but also weight-for-height was affected by differences between the studies other than the covar-
iates, indicating that differences may be due to the provision of LNS.
Age-specific analysis
As mentioned previously, anthropometric assessments were completed only at the beginning
and end of the study in the non-intervention groups, and these groups were not included in
the morbidity surveillance. Thus, results for age-specific intervals and for morbidity surveil-
lance are available only for the intervention cohorts (Fig 1).
The sample size per study group and age range included in the present analyses ranged
from 185 to 221 in the Z-Contr group and 769 to 975 in the two supplemented groups
(Z-Suppl and LNS) during the different study rounds (Table 4). Children in the Z-Contr
Fig 3. Difference in change in length-for-age z-score between the LNS and the zinc study populations over the whole study duration.
https://doi.org/10.1371/journal.pone.0181770.g003
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group were significantly older (12.3 ± 2.4 mo) than children in the Z-Suppl group (10.1 ± 2.7
mo) and the LNS-IC group (9.4 ± 0.4 mo; p<0.0001). However, baseline LAZ, WAZ and
WLZ were not significantly different among the 3 groups with or without adjustment for age
(Table 5). Maternal age, height, BMI, education, marital status and ethnic group differed sig-
nificantly among the 3 groups. The morbidity burden was highest in the LNS group (Table 4).
In particular, malaria prevalence and incidence were significantly higher in the LNS group
compared to the other two study groups. Although treatment coverage differed between the
two studies, it was high in all study groups. In particular, 99.5% of all identified malaria cases
were treated in the LNS group, 90.1% in the Z-Suppl group and 94.8% in the Z-Contr group
(P<0.0001). Diarrhea prevalence tended to be higher in the LNS and the Z-Contr groups com-
pared to the Z-Suppl group (Table 4) and 38.7% of all diarrhea cases were treated in the LNS
group compared to 30.0% in the Z-Contr and 29.2% in the Z-Suppl groups, respectively (P<
0.0001). In summary, child age at enrollment as well as several maternal characteristics and the
Table 3. Comparison of the change in length-for-age z-score, weight-for-age z-score, and weight-for-length z-score between the LNS and the zinc
study populations over the whole study duration.1
Adjusted means Interaction
coefficient
p-value
Model LNS-IC LNS-NIC Z-IC Z-NIC Study Intervention Study*intervention
Change in LAZ
A: No covariates2 -0.146 ± 0.047 -0.550 ± 0.076 -0.676 ± 0.050 -0.551 ± 0.060 0.529 ± 0.119 < .0001 0.022 < .0001
B: Initial LAZ, initial WLZ,
age at midpoint, time
between measurements
(covariate only)
-0.044 ± 0.129 -0.475 ± 0.126 -0.797 ± 0.146 -0.622 ± 0.148 0.607 ± 0.123 0.080 0.038 < .0001
C: Above plus child sex
and maternal covariates3
-0.095 ± 0.127 -0.483 ± 0.124 -0.729 ± 0.155 -0.657 ± 0.156 0.459 ± 0.152 0.120 0.012 0.004
Change in WAZ
A: No covariates2 0.212 ± 0.037 -0.103 ± 0.065 -0.185 ± 0.047 -0.124 ± 0.053 0.376 ± 0.103 0.0001 0.017 0.0005
B: Initial WAZ, age at
midpoint, time between
measurements (covariate
only)
0.366 ± 0.125 -0.003 ± 0.115 -0.382 ± 0.144 -0.232 ± 0.142 0.519 ± 0.097 0.055 0.023 < .0001
C: Above plus child sex
and maternal covariates3
0.355 ± 0.125 -0.014 ± 0.115 -0.362 ± 0.154 -0.283 ± 0.151 0.447 ± 0.132 0.058 0.005 0.002
Change in WLZ
A: No covariates2 0.232 ± 0.044 0.090 ± 0.077 0.030 ± 0.054 0.035 ± 0.062 0.147 ± 0.121 0.036 0.263 0.226
B: Initial LAZ, initial WLZ,
age at midpoint, time
between measurements
(covariate only)
0.475 ± 0.135 0.232 ± 0.125 -0.262 ± 0.156 -0.184 ± 0.154 0.321 ± 0.105 0.037 0.109 0.003
C: Above plus maternal
and child covariates3
0.443 ± 0.133 0.187 ± 0.123 -0.245 ± 0.165 -0.191 ± 0.161 0.310 ± 0.139 0.056 0.050 0.031
LAZ, length-for-age z-score; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score
1adjusted mean ± SE
2Fixed main effect of study (LNS vs. zinc study) and intervention (IC vs NIC), along with fixed interaction term and random effects of village and concession
within village
3Maternal covariates included in the model were: height, BMI, age, marital status (first wife), ethnic group, maternal education
https://doi.org/10.1371/journal.pone.0181770.t003
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morbidity burden were identified as potential confounders and these were included in the
model described below.
In Table 6 we show the effect of adding covariates to the model on the differences in mean
changes of LAZ, WAZ and WLZ from 9 to 12 months of age. Unadjusted change in LAZ from
9 to 12 months of age was significantly different between LNS and Z-Suppl and between LNS
and Z-Contr, but not between Z-Suppl and Z-Contr. Adding the time between the anthropo-
metric assessments (model 1) along with child age and seasonality (model 2) attenuates the dif-
ference in mean change between LNS and Z-Suppl and between LNS and Z-Contr somewhat,
but the differences remain significant. The differences disappear between LNS and Z-Contr as
enrollment covariates are added to the model, but remain marginally significant between LNS
and Z-Suppl (model 4). Adding the morbidity prevalence and incidence during the specific
age interval to the model increases the difference in mean changes of LAZ between LNS and
Z-Suppl, implying that the morbidity burden and treatment provided did not explain the dif-
ference in growth impact observed between these groups with previous models. Similarly, add-
ing covariates to the model does not explain the differences in mean changes of WAZ. The
differences in mean changes in WAZ remain significant between LNS and Z-Suppl and LNS
and Z-Contr after adding baseline characteristics, morbidity burden and baseline anthropo-
metric Z-scores. While this is also true for the differences in mean changes in WLZ between
LNS and Z-Contr, the differences in mean changes in WLZ between LNS and Z-Suppl are no
longer significant in the adjusted models. Table 7 shows that differences in mean change in
LAZ from 12 to 15 months of age remain significantly different between LNS and Z-Suppl and
between LNS and Z-Contr throughout the increasingly adjusted model, implying that the
impact found on growth in the LNS group could not be explained by any of the covariates
tested. The unadjusted group differences were not significant for mean changes of WAZ and
Table 4. Prevalence of malaria, fever and diarrhea during the different age intervals.
Age group LNS Z-Contr Z-Suppl P-value
N1 9–12 mo 975 183 768
12–15 mo 827 220 803
15–18 mo 793 203 881
Malaria prevalence (%) 9–12 mo 1.30 (0.07) a 0.57 (0.10) b 0.60 (0.04) b <0.0001
12–15 mo 1.60 (0.09) a 0.69 (0.09) b 0.49 (0.04) c <0.0001
15–18 mo 1.36 (0.08) a 0.80 (0.09) b 0.54 (0.03) c <0.0001
Fever prevalence (%) 9–12 mo 3.34 (0.12) a 2.98 (0.22) a 2.24 (0.10) b <0.0001
12–15 mo 3.27 (0.13) a 3.31 (0.21) a 2.00 (0.09) b <0.0001
15–18 mo 3.02 (0.13) a 3.20 (0.25) a 1.79 (0.07) b <0.0001
Diarrhea prevalence (%) 9–12 mo 3.24 (0.15) a 2.08 (0.22) b 2.15 (0.11) b <0.0001
12–15 mo 2.78 (0.15) a 2.24 (0.21) ab 1.79 (0.10) b <0.0001
15–18 mo 2.26 (0.14) a 2.16 (0.30) a 1.36 (0.09) b <0.0001
Acute upper respiratory infection prevalence (%) 9–12 mo 7.48 (0.49) a 1.92 (0.40) b 1.34 (0.14) b <0.0001
12–15 mo 6.91 (0.44) a 2.06 (0.34) b 1.26 (0.12) c <0.0001
15–18 mo 7.17 (0.48) a 2.50 (0.40) b 1.23 (0.10) c <0.0001
Acute lower respiratory infection prevalence (%) 9–12 mo 0.11 (0.05) 0.07 (0.03) 0.09 (0.02) 0.856
12–15 mo 0.05 (0.02) 0.04 (0.03) 0.04 (0.01) 0.882
15–18 mo 0.05 (0.02) 0.08 (0.03) 0.04 (0.01) 0.562
Prevalences were defined as number of days with illness per 100 days of observation, and were compared between groups with mixed models Poisson
regression (SAS GENMOD procedure), with overdispersion adjustment. Rows with different superscripts differ significantly (p<0.05)
1 Sample size for different morbidity outcomes may vary slightly.
https://doi.org/10.1371/journal.pone.0181770.t004
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WLZ from 12 to 15 months, nor for mean change in LAZ, WAZ and WLZ from 15 to 18
months. Thus those models are not shown. The differences in mean change in LAZ from 9 to
12 months and 12 to 15 months of age between LNS and Z-Suppl are shown in Fig 4.
Continued breastfeeding was very common in both study areas (>99%), but only a small
portion of children met the minimum requirement for adequate dietary diversity [21]. Adding
breastfeeding and adequate dietary diversity to the model did not affect the differences in
mean changes in LAZ, WAZ and WLZ during any of the age-specific intervals (data not
shown).
Discussion
The present exploratory analyses of change in LAZ and WAZ during age-specific intervals
indicated that the supplement type was likely responsible for the significant differences in
change in LAZ and WAZ observed from 9 to 12 months and in LAZ from 12 to 15 months
between children in the LNS and zinc supplementation trials. Although differences in study
Table 5. Comparison of baseline characteristics of children in the exploratory analyses of the LNS and zinc intervention trials by age range.1
LNS Z-Contr Z-Suppl p-value p-value after controlling for age at
enrollment
N 1716 610 1720
Child characteristics
Age (mo) 9.4 ± 0.4 12.3 ± 2.4 10.1 ± 2.7 <0.0001 n/a
Male 877 (51.1) 302 (49.5) 882 (51.3) 0.74 n/a
Hemoglobin (g/L) 89.8 ± 15.5 90.4 ± 14.1 92.3 ± 14.6 0.041 0.049
Length (cm) 68.8 ± 2.6 71.6 ± 3.6 69.5 ± 4.1 <0.0001 0.30
Weight (kg) 7.42 ± 0.98 7.93 ± 1.11 7.58 ± 1.16 <0.0001 0.44
MUAC (cm) 13.32 ± 1.16 13.47 ± 1.11 13.45 ± 1.20 0.08 0.07
LAZ -1.22 ± 1.09 -1.38 ± 1.20 -1.18 ± 1.19 0.12 0.11
WAZ -1.43 ± 1.12 -1.48 ± 1.15 -1.36 ± 1.18 0.22 0.17
WLZ -1.00 ± 1.05 -1.06 ± 1.00 -0.95 ± 1.07 0.066 0.26
BMIZ -0.99 ± 1.05 -0.92 ± 0.98 -0.93 ± 1.07 0.30 0.35
MUACZ -0.95 ± 1.09 -0.91 ± 1.04 -0.84 ± 1.12 0.030 0.039
Breastfeeding in past 24hrs, n (%) 1715 (99.9) 586 (99.8) 1663 (99.5) 0.085 0.095
Minimum dietary diversity, n(%)2 208 (12.1) 144 (26.7) 242 (15.2) <0.0001 0.93
Maternal characteristics
Maternal age (yrs) 27.1 ± 6.9 25.8 ± 6.7 26.1 ± 6.4 <0.0001 n/a
Maternal height (cm) 162.3 ± 5.7 160.1 ± 5.7 159.8 ± 6.1 <0.0001 n/a
Maternal BMI (kg/m2) 20.9 ± 2.5 21.2 ± 2.5 21.3 ± 2.5 0.003 n/a
Maternal education, n (% with any formal
education)
185 (10.9) 113 (19.0) 330 (19.7) 0.003 n/a
Mother is first or only wife, n (%) 1251 (73.3) 346 (58.2) 965 (57.7) <0.0001 n/a
Maternal religion 0.49 n/a
Muslim, n (%) 1412 (82.8) 471 (80.1) 1276 (78.3)
Traditional, n (%) 160 (9.4) 75 (12.8) 264 (16.2)
Christian, n (%) 134 (7.9) 38 (6.5) 89 (5.5)
BMI, body mass index; BMIZ, z-score of body mass index; LAZ, length-for-age z-score; MUAC, mid-upper arm circumference; MUACZ; z-score of mid-
upper arm circumference; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score
1 mean ± SD, and n (%); all such values.
2 Child received food from 4 or more food groups during the previous 24 h [21]
https://doi.org/10.1371/journal.pone.0181770.t005
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duration, seasonality and maternal and child socio-economic characteristics explained some
of the differences in study-specific growth patterns, the effect of the supplement type remained
significant even after controlling for these other factors. Likewise, the difference in anthropo-
metric outcomes between trials was not explained by differences in morbidity prevalence or
incidence. Thus, the present analyses suggest that the difference in study results is likely due at
least in part to the fact that children in the LNS study received small-quantity LNS. Consider-
ing that the difference in mean change in LAZ occurred when children where 9 to 15 months
Table 6. The change and the difference in mean changes of length-for-age z-score, weight-for-age z-score and weight-for-length z-score from 9 to
12 months of age as different covariates are added to the mixed-model analysis of covariance.
Model Adjusted means of LAZ Difference in mean changes of LAZ P-values for differences
Z-Contr Z-Suppl LNS Z-Suppl vs
Z-Contr
LNS vs
Z-Contr
LNS vs
Z-Suppl
Z-Suppl vs
Z-Contr
LNS vs
Z-Contr
LNS vs
Z-Suppl
Change in LAZ from 9–12 months
1: No covariates -0.308
(0.036)
-0.307
(0.021)
-0.088
(0.022)
0.001 0.22 0.219 0.100 < .0001 < .0001
2: Time between measurements
only
-0.297
(0.042)
-0.295
(0.031)
-0.099
(0.031)
0.002 0.198 0.196 0.999 0.003 0.001
3: Time between measurements,
age at midpoint, season
-0.283
(0.043)
-0.293
(0.031)
-0.105
(0.031)
-0.01 0.178 0.188 0.965 0.010 0.001
4: Above plus covariates at
enrollment
-0.240
(0.043)
-0.267
(0.033)
-0.138
(0.030)
-0.028 0.102 0.13 0.783 0.213 0.055
5: Above plus morbidity prevalence
and incidence
-0.260
(0.043)
-0.286
(0.033)
-0.119
(0.030)
-0.027 0.14 0.167 0.793 0.057 0.009
6: Above plus LAZ, WAZ and WLZ
at start of age-specific period
-0.255
(0.042)
-0.279
(0.033)
-0.124
(0.030)
-0.024 0.132 0.156 0.829 0.078 0.016
Change in WAZ from 9–12 months
1: No covariates -0.150
(0.040)
-0.103
(0.019)
0.157
(0.017)
0.047 0.307 0.26 0.536 < .0001 < .0001
2: Time between measurements
only
-0.140
(0.047)
-0.092
(0.032)
0.147
(0.030)
0.047 0.286 0.239 0.531 < .0001 0.0001
3: Time between measurements,
age at midpoint, season
-0.132
(0.047)
-0.088
(0.033)
0.142
(0.031)
0.044 0.274 0.23 0.580 0.0002 0.0002
4: Above plus covariates at
enrollment
-0.099
(0.047)
-0.039
(0.035)
0.099
(0.030)
0.059 0.197 0.138 0.387 0.009 0.058
5: Above plus morbidity prevalence
and incidence
-0.114
(0.047)
-0.057
(0.035)
0.113
(0.030)
0.056 0.226 0.17 0.421 0.002 0.014
6: Above plus LAZ, WAZ and WLZ
at start of age-specific period
-0.115
(0.047)
-0.059
(0.035)
0.114
(0.030)
0.056 0.228 0.172 0.419 0.002 0.013
Change in WLZ from 9–12 months
1: No covariates -0.150
(0.050)
-0.068
(0.026)
0.144
(0.025)
0.082 0.294 0.212 0.3021 < .0001 < .0001
2: Time between measurements
only
-0.125
(0.059)
-0.042
(0.042)
0.119
(0.040)
0.083 0.245 0.161 0.2949 0.01 0.0716
3: Time between measurements,
age at midpoint, season
-0.124
(0.059)
-0.040
(0.041)
0.116
(0.040)
0.084 0.24 0.156 0.288 0.012 0.0819
4: Above plus covariates at
enrollment
-0.118
(0.056)
-0.008
(0.042)
0.085
(0.036)
0.11 0.204 0.094 0.1008 0.0276 0.3919
5: Above plus morbidity prevalence
and incidence
-0.126
(0.056)
-0.021
(0.042)
0.093
(0.036)
0.104 0.219 0.114 0.1253 0.0166 0.2506
6: Above plus LAZ, WAZ and WLZ
at start of age-specific period
-0.130
(0.056)
-0.024
(0.042)
0.096
(0.036)
0.106 0.225 0.12 0.1175 0.0128 0.2193
https://doi.org/10.1371/journal.pone.0181770.t006
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of age, the results suggest that providing LNS to children at younger age rather than later may
result in improved growth, and thus may help prevent stunting [14].
Findings from longitudinal studies investigating the impact of malaria on linear growth are
inconsistent [25–29]. Because the malaria prevalence differed between the two study sites in
Burkina Faso, we explored whether these illnesses explained the growth differences. However,
malaria prevalence and incidence was actually greater in the Dande´ Health District, where the
LNS study was conducted, and the inclusion of malaria prevalence and incidence into the
attenuation model did not affect the observed differences in growth. Thus, malaria was not
responsible for the observed growth differences in these studies where malaria surveillance
and treatment coverage were very high (>90%).
Several multi-country studies found that diarrhea was associated with a slightly reduced lin-
ear growth over the long term [30–32]. Diarrhea prevalence was significantly higher among the
Table 7. The change and the difference in mean changes of LAZ from 12 to 15 months of age as different covariates are added to the mixed-model
analysis of covariance.
Model Adjusted means of LAZ Difference in mean changes of LAZ P-values for differences
Z-Contr Z-Suppl LNS Z-Suppl vs
Z-Cont
LNS vs
Z-Contr
LNS vs
Z-Suppl
Z-Suppl vs
Z-Cont
LNS vs
Z-Cont
LNS vs
Z-Suppl
Change in LAZ from 12–15 months
1: No covariates -0.257
(0.032)
-0.228
(0.020)
-0.073
(0.022)
0.029 0.184 0.155 0.689 < .0001 < .0001
2: Time between measurements only -0.255
(0.034)
-0.226
(0.024)
-0.075
(0.026)
0.03 0.18 0.151 0.686 0.0003 0.0007
3: Time between measurements, age
at midpoint, season
-0.255
(0.033)
-0.252
(0.023)
-0.057
(0.025)
0.004 0.198 0.195 0.994 < .0001 < .0001
4: Above plus covariates at
enrollment
-0.257
(0.043)
-0.243
(0.025)
-0.065
(0.028)
0.014 0.192 0.178 0.948 0.004 0.0003
5: Above plus morbidity prevalence
and incidence
-0.263
(0.044)
-0.258
(0.026)
-0.049
(0.029)
0.005 0.214 0.209 0.994 0.001 < .0001
6: Above plus LAZ, WAZ and WLZ at
start of age-specific period
-0.257
(0.043)
-0.248
(0.027)
-0.058
(0.031)
0.009 0.199 0.191 0.979 0.003 0.0003
https://doi.org/10.1371/journal.pone.0181770.t007
Fig 4. The difference in mean changes in length-for-age z-score between the LNS and the Z-Suppl groups from 9 to 12 and 12 to 15 months of age
as different covariates are added to the mixed-model analysis of covariance.
https://doi.org/10.1371/journal.pone.0181770.g004
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LNS study children compared with Z-Suppl in all age intervals. Adding diarrhea prevalence and
incidence to the attenuation model did not significantly affect the results for LAZ from 9 to 12
months and 12 to 15 months of age, nor for WAZ from 9 to 12 months of age, indicating that
diarrhea was not responsible for the observed study-wise difference in change in growth.
Inclusion of the interval duration between anthropometric measurements and seasonality
attenuated the differences in change of growth to a small degree, but the differences remained
significant in both the analysis over the whole study period and the age-specific interval analy-
ses. Thus, study design characteristics (i.e. time between anthropometric measurements and
seasonality) were not completely responsible for observed growth effects. Similarly, children’s
baseline anthropometric status, sex and age only affected growth to a small extent.
Several other studies have also found enhanced growth in response to small-quantity LNS,
although results are inconsistent among studies. Adu-Afarwuah and colleagues found a ten-
dency towards improved growth with small-quantity LNS (standardized mean difference of
final LAZ of 0.26 between Ghanaian children who received small-quantity LNS from 6 to 12
months compared to children in a non-intervention group), although the difference in final
LAZ at 12 months of age was not statistically significant [11]. Small-quantity LNS supplemen-
tation for 6 months significantly increased the LAZ (±SE) by 0.13 ± 0.05 in young children in
Haiti [12]. This finding is in contrast to a study in Malawi, where the provision of 10, 20 and
40 g of LNS for 12 months to young Malawian children did not prevent growth faltering [9].
An earlier randomized trial in young Malawian children with mean initial LAZ of -1.00 ± 0.77
found that only infants with baseline LAZ below the median who received 50 g LNS gained
more length than children who received a micronutrient-fortified maize-soy flour for 12
months [10]. The reasons for these inconsistent growth impacts of small quantity LNS need
further investigation.
The strengths and weaknesses of the individual studies included in the present exploratory
analyses have been reported previously [14,19]. However, limitations of the present analyses
have to be considered. First, for simplicity of interpretation, we assumed for all covariates and
outcomes that there were no appreciable group by covariate interactions in the age-specific
analysis or study by cohort by covariate interactions in the whole-study analysis. Second,
except at the time of initial enrollment into the study, anthropometric assessments at the
beginning of any age-specific interval could not be used as covariates, because growth out-
comes may have been affected by the prior intervention and therefore show different patterns
over time. Thus, we included them in the final models only as mediating variables. Third,
other factors not measured in the present analyses may have contributed to the growth impact.
In particular, the two studies were implemented in different health districts. Although they
were in close geographic proximity, we cannot distinguish between study-related and site-
related characteristics. The study fixed effect accounted for part of these site differences in the
full study analysis, but was not used in the age-interval analysis because it was confounded
with LNS provision. Last, we included all available morbidity results into the analyses indepen-
dent of treatment, even though treatment coverage differed between the two studies. However,
morbidity variables were only weakly related to growth (absolute correlation ranged from
0.002 to 0.106), and therefore including morbidity in the model had little effect. A main limita-
tion was related to the original study designs of the LNS and the zinc supplementation studies.
Namely, weekly morbidity surveillance was not done in the NIC, thus we were not able to
compare the morbidity burden in the intervention communities and NIC. It is likely that the
prevalence of untreated illnesses differed between intervention communities and the NICs,
and possible that untreated illnesses had a stronger relationship with growth than treated ill-
nesses. However, for ethical reasons we offered treatment for documented episodes of malaria
and diarrhea.
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Conclusions
The present analyses suggest that the difference in growth between the LNS and the zinc sup-
plementation studies is likely at least partly due to small-quantity LNS. Although differences in
study design and maternal and child socio-economic characteristics explained some of the
study-related differences in observed growth, the effect of the supplement type on LAZ and
WAZ remained after controlling for these other factors, and was not explained by differences
in morbidity prevalence or incidence. Therefore, the results suggest that providing LNS to chil-
dren from 9 to 15 months in this setting increases child growth.
Acknowledgments
We appreciate valuable comments on the manuscript by Kathryn G. Dewey (University of Cal-
ifornia, Davis).
Author Contributions
Conceptualization: Sonja Y. Hess, Janet M. Peerson, Kenneth H. Brown.
Data curation: Janet M. Peerson, Elodie Becquey, Souheila Abbeddou, Ce´saire T. Oue´draogo,
Je´roˆme W. Some´.
Formal analysis: Janet M. Peerson.
Funding acquisition: Sonja Y. Hess.
Investigation: Sonja Y. Hess, Janet M. Peerson, Elodie Becquey, Souheila Abbeddou, Ce´saire
T. Oue´draogo, Je´roˆme W. Some´, Elizabeth Yakes Jimenez, Jean-Bosco Oue´draogo, Stephen
A. Vosti, Noe¨l Rouamba, Kenneth H. Brown.
Methodology: Janet M. Peerson.
Project administration: Sonja Y. Hess, Janet M. Peerson, Elodie Becquey, Souheila Abbeddou,
Ce´saire T. Oue´draogo, Je´roˆme W. Some´, Elizabeth Yakes Jimenez, Jean-Bosco Oue´draogo,
Stephen A. Vosti, Noe¨l Rouamba, Kenneth H. Brown.
Software: Janet M. Peerson.
Supervision: Sonja Y. Hess, Jean-Bosco Oue´draogo, Stephen A. Vosti, Noe¨l Rouamba, Ken-
neth H. Brown.
Validation: Janet M. Peerson.
Visualization: Janet M. Peerson.
Writing – original draft: Sonja Y. Hess.
Writing – review & editing: Sonja Y. Hess, Janet M. Peerson, Elodie Becquey, Souheila
Abbeddou, Ce´saire T. Oue´draogo, Je´roˆme W. Some´, Elizabeth Yakes Jimenez, Jean-Bosco
Oue´draogo, Stephen A. Vosti, Noe¨l Rouamba, Kenneth H. Brown.
References
1. Victora CG, Adair L, Fall C, Hallal PC, Martorell R, Richter L, et al. Maternal and child undernutrition:
consequences for adult health and human capital. Lancet. 2008; 371: 340–357. https://doi.org/10.1016/
S0140-6736(07)61692-4 PMID: 18206223
2. Division for Sustainable Development, United Nations Department of Economic and Social Affairs Sus-
tainable Development Knowledge Platform. New York, NY, USA: United Nations Department of Eco-
nomic and Social Affairs. 2016.
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 17 / 19
3. de Onis M, Dewey KG, Borghi E, Onyango AW, Blossner M, Daelmans B, et al. The World Health Orga-
nization’s global target for reducing childhood stunting by 2025: rationale and proposed actions. Matern
Child Nutr. 2013; 9 Suppl 2: 6–26.
4. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernu-
trition and overweight in low-income and middle-income countries. Lancet. 2013; 382: 427–451. https://
doi.org/10.1016/S0140-6736(13)60937-X PMID: 23746772
5. Stewart CP, Iannotti L, Dewey KG, Michaelsen KF, Onyango AW. Contextualising complementary feed-
ing in a broader framework for stunting prevention. Matern Child Nutr. 2013; 9 Suppl 2: 27–45.
6. Arimond M, Zeilani M, Jungjohann S, Brown KH, Ashorn P, Allen LH, et al. Considerations in developing
lipid-based nutrient supplements for prevention of undernutrition: experience from the International
Lipid-Based Nutrient Supplements (iLiNS) Project. Matern Child Nutr. 2013: [epub ahead of print];
https://doi.org/10.1111/mcn.12049 PMID: 23647784
7. Lenters LM, Wazny K, Webb P, Ahmed T, Bhutta ZA. Treatment of severe and moderate acute malnu-
trition in low- and middle-income settings: a systematic review, meta-analysis and Delphi process. BMC
Public Health. 2013; 13 Suppl 3: S23.
8. Ackatia-Armah R, McDonald C, Doumbia S, Erhardt J, Hamer D, Brown K. Malian children with moder-
ate acute malnutrition who are treated with lipid-based dietary supplements have greater weight gains
and recovery rates than those treated with locally produced cereal-legume products: a community-
based, cluster-randomized trial Am J Clin Nutr. 2015: ajcn.069807; First published online January
069807, 062015.
9. Maleta KM, Phuka J, Alho L, Cheung YB, Dewey KG, Ashorn U, et al. Provision of 10–40 g/d Lipid-
Based Nutrient Supplements from 6 to 18 Months of Age Does Not Prevent Linear Growth Faltering in
Malawi. J Nutr. 2015; 145: 1909–1915. https://doi.org/10.3945/jn.114.208181 PMID: 26063066
10. Phuka JC, Maleta K, Thakwalakwa C, Cheung YB, Briend A, Manary MJ, et al. Complementary feeding
with fortified spread and incidence of severe stunting in 6- to 18-month-old rural Malawians. Arch
Pediatr Adolesc Med. 2008; 162: 619–626. https://doi.org/10.1001/archpedi.162.7.619 PMID:
18606932
11. Adu-Afarwuah S, Lartey A, Brown KH, Zlotkin S, Briend A, Dewey KG. Randomized comparison of 3
types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on
growth and motor development. Am J Clin Nutr. 2007; 86: 412–420. PMID: 17684213
12. Iannotti LL, Dulience SJ, Green J, Joseph S, Francois J, Antenor ML, et al. Linear growth increased in
young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supple-
ment. Am J Clin Nutr. 2013; 99: 198–208. https://doi.org/10.3945/ajcn.113.063883 PMID: 24225356
13. Adu-Afarwuah S, Lartey A, Okronipa H, Ashorn P, Peerson JM, Arimond M, et al. Small-quantity, lipid-
based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their
infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana:
a randomized controlled trial. Am J Clin Nutr. 2016; 104: 797–808. https://doi.org/10.3945/ajcn.116.
134692 PMID: 27534634
14. Hess SY, Abbeddou S, Jimenez EY, Some JW, Vosti SA, Ouedraogo ZP, et al. Small-quantity lipid-
based nutrient supplements, regardless of their zinc content, increase growth and reduce the preva-
lence of stunting and wasting in young burkinabe children: a cluster-randomized trial. PLoS One. 2015;
10: e0122242. https://doi.org/10.1371/journal.pone.0122242 PMID: 25816354
15. Brown KH, Peerson JM, Rivera J, Allen LH. Effect of supplemental zinc on the growth and serum zinc
concentrations of prepubertal children: a meta-analysis of randomized controlled trials. Am J Clin Nutr.
2002; 75: 1062–1071. PMID: 12036814
16. Brown KH, Peerson JM, Baker SK, Hess SY. Preventive zinc supplementation among infants, pre-
schoolers, and older prepubertal children. Food Nutr Bull. 2009; 30: S12–40. https://doi.org/10.1177/
15648265090301S103 PMID: 19472600
17. Imdad A, Bhutta ZA. Effect of preventive zinc supplementation on linear growth in children under 5
years of age in developing countries: a meta-analysis of studies for input to the lives saved tool. BMC
Public Health. 2011; 11 Suppl 3: S22.
18. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XH, Chan ES, et al. Zinc supplementation for pre-
venting mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. Cochrane
Database Syst Rev. 2014; 5: CD009384.
19. Becquey E, Ouedraogo CT, Hess SY, Rouamba N, Prince L, Ouedraogo JB, et al. Comparison of Pre-
ventive and Therapeutic Zinc Supplementation in Young Children in Burkina Faso: A Cluster-Random-
ized, Community-Based Trial. J Nutr. 2016.
20. World Health Organization Physical status: The use and interpretation of anthropometry. Technical
Report Series No. 854. Geneva: World Health Organization. 1995.
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 18 / 19
21. World Health Organization Indicators of assessing infant and young child feeding practices. Conclu-
sions of a consensus meeting held 6–8 November 2007 in Washington, DC Geneva: World Health
Organization 2008.
22. WHO Multicentre Growth Reference Study Group WHO Child Growth Standards: Length/height-for-
age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and
development. Geneva: World Health Organization. 2006.
23. WHO Multicentre Growth Reference Study Group WHO Child Growth Standards: Head circumference-
for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular skinfold-for-age: Methods
and development. Geneva: World Health Organization. 2007.
24. Some JW, Abbeddou S, Yakes Jimenez E, Hess SY, Ouedraogo ZP, Guissou RM, et al. Effect of zinc
added to a daily small-quantity lipid-based nutrient supplement on diarrhoea, malaria, fever and respira-
tory infections in young children in rural Burkina Faso: a cluster-randomised trial. BMJ Open. 2015; 5:
e007828. https://doi.org/10.1136/bmjopen-2015-007828 PMID: 26362661
25. Nyakeriga AM, Troye-Blomberg M, Chemtai AK, Marsh K, Williams TN. Malaria and nutritional status in
children living on the coast of Kenya. Am J Clin Nutr. 2004; 80: 1604–1610. PMID: 15585775
26. Padonou G, Le Port A, Cottrell G, Guerra J, Choudat I, Rachas A, et al. Prematurity, intrauterine growth
retardation and low birth weight: risk factors in a malaria-endemic area in southern Benin. Trans R Soc
Trop Med Hyg. 2014; 108: 77–83. https://doi.org/10.1093/trstmh/trt099 PMID: 24336697
27. Kang H, Kreuels B, Adjei O, Krumkamp R, May J, Small DS. The causal effect of malaria on stunting: a
Mendelian randomization and matching approach. Int J Epidemiol. 2013; 42: 1390–1398. https://doi.
org/10.1093/ije/dyt116 PMID: 23925429
28. Lee G, Yori P, Olortegui MP, Pan W, Caulfield L, Gilman RH, et al. Comparative effects of vivax malaria,
fever and diarrhoea on child growth. Int J Epidemiol. 2012; 41: 531–539. https://doi.org/10.1093/ije/
dyr190 PMID: 22258823
29. Deen JL, Walraven GE, von Seidlein L. Increased risk for malaria in chronically malnourished children
under 5 years of age in rural Gambia. J Trop Pediatr. 2002; 48: 78–83. PMID: 12022433
30. Checkley W, Buckley G, Gilman RH, Assis AM, Guerrant RL, Morris SS, et al. Multi-country analysis of
the effects of diarrhoea on childhood stunting. Int J Epidemiol. 2008; 37: 816–830. https://doi.org/10.
1093/ije/dyn099 PMID: 18567626
31. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Lanata CF, et al. Diarrhea in early childhood:
short-term association with weight and long-term association with length. Am J Epidemiol. 2013; 178:
1129–1138. https://doi.org/10.1093/aje/kwt094 PMID: 23966558
32. Richard SA, Black RE, Gilman RH, Guerrant RL, Kang G, Lanata CF, et al. Catch-up growth occurs
after diarrhea in early childhood. J Nutr. 2014; 144: 965–971. https://doi.org/10.3945/jn.113.187161
PMID: 24699805
Differing growth responses to nutritional supplements in neighboring health districts in Burkina Faso
PLOS ONE | https://doi.org/10.1371/journal.pone.0181770 August 3, 2017 19 / 19
